-
Uncategorized6 months agoBlackstone closes $6.3B fund for life sciences investing
It's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle. Read More
-
Uncategorized6 months agoSTAT+: Doctors Without Borders calls Gilead ‘unconscionable’ for refusing to sell HIV prevention drug to organization
In the latest dustup over a groundbreaking HIV prevention medicine, Doctors Without Borders has harshly criticized the manufacturer for refusing to sell its treatment directly to...
-
Uncategorized6 months agoAutism Risk Genes Largely Shared Across Global Populations
Over the past decade, scientists have identified numerous genetic variants that confer substantial risk for autism and other neurodevelopmental disorders. However, most of these discoveries were...
-
Uncategorized6 months ago
#ACC26: Merck touts comparator data for oral cholesterol drug
Merck’s drug enlicitide beat a handful of commonly used cholesterol-lowering drugs in a comparator trial, inching it closer to becoming the first oral PCSK9 inhibitor. The...
-
Uncategorized6 months agoLilly’s AI commitment expands through deal with Insilico
A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks to sustain its industry lead. Read More
-
Uncategorized6 months ago
Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?
Viridian Therapeutics’ shares dropped Monday morning after a lackluster pivotal readout on its injection to treat thyroid eye disease. Viridian’s pitch is that its drug, known...
-
Uncategorized6 months ago
Blackstone raises $6.3B life sciences fund in record fundraising haul
The life sciences industry’s largest-ever private investment fund has arrived, and it comes from the world’s biggest alternative asset manager. On Monday, Blackstone announced it had...
-
Uncategorized6 months agoSTAT+: Early signs of Alzheimer’s often go undetected. These researchers want to change that
Researchers in Massachusetts are experimenting with artificial intelligence to detect signs of Alzheimer’s disease in its earliest stages, when symptoms of the dreaded illness may go...
-
Uncategorized6 months ago
Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies
Two separate randomized trials failed to illustrate Impella’s benefits in specific cases of patients with blocked coronary arteries.
-
Uncategorized6 months agoEli Lilly and Insilico agree AI-driven drug discovery alliance
Eli Lilly and Insilico Medicine have announced a drug discovery collaboration that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across...
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
Deep dive: Psychedelics back on FDA’s doorstep
‘Patients are not a renewable resource’: Rethinking rare disease R&D
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
